请输入您的用户名或电子邮件地址。您将收到一个链接,通过电子邮件创建一个新密码。
© 2023 MergersCorp M&A International. © 2022 MergersCorp™ M&A International is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://www.mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.
This website is operated by MergersUS Inc.a US Corporation with registered office at 40th Wall Street, Suite #2725, New York, New York 10005, United States of America.
自 2017 年以来,该公司作为一家技术公司,一直致力于生物医学领域的合成骨组织和软骨组织支架。它在埃格大学技术开发中心和 ISO-5(100 级)、ISO-6(1000 级)和 ISO-7( 10000 级)马尼萨的洁净室条件。
它是一家生物技术公司,专注于创新合成骨移植产品的设计、开发、制造和营销。除了拥有高科技的生产和质量控制设备外,在其专业员工和强大的资本结构的支持下,它还不间断地继续进行研发投资。
它是土耳其合成骨移植市场三大制造商中最大的,也是最大的出口商。凭借其以出口为导向的增长战略,它已在 3 年内完成了在 55 个国家的认证程序并出口到这些国家。它面向国外的市场占总市场的 3096 个。
在获得 FDA 批准后,它将继续在美国和亚太地区进行增长研究。
脊柱外科仍然工作繁重,旨在在骨科和牙科领域迅速发展。截至 2021 年,它将通过 3 款新产品提高其在市场上的有效性。
Gross Revenue
TBA
EBITDA
TBA
Business ID:
L#20210180
Country
土耳其
Business ID: | L#20210180 |
财产种类: | 制造业 |
物业状况: | 待售 |
Target Price: | €8,000,000 |
Gross Revenue: | TBA |
EBITDA: | TBA |
Target Price / Revenue: | INFx |
Target Price / EBITDA: | INFx |
更新 3月 16, 2023 在 5:50 下午
自 2017 年以来,该公司作为一家技术公司,一直致力于生物医学领域的合成骨组织和软骨组织支架。它在埃格大学技术开发中心和 ISO-5(100 级)、ISO-6(1000 级)和 ISO-7( 10000 级)马尼萨的洁净室条件。
它是一家生物技术公司,专注于创新合成骨移植产品的设计、开发、制造和营销。除了拥有高科技的生产和质量控制设备外,在其专业员工和强大的资本结构的支持下,它还不间断地继续进行研发投资。
它是土耳其合成骨移植市场三大制造商中最大的,也是最大的出口商。凭借其以出口为导向的增长战略,它已在 3 年内完成了在 55 个国家的认证程序并出口到这些国家。它面向国外的市场占总市场的 3096 个。
在获得 FDA 批准后,它将继续在美国和亚太地区进行增长研究。
脊柱外科仍然工作繁重,旨在在骨科和牙科领域迅速发展。截至 2021 年,它将通过 3 款新产品提高其在市场上的有效性。
© 2023 MergersCorp M&A International © 2022 MergersCorp™ M&A International is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://www.mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.
This website is operated by MergersUS Inc.a US Corporation with registered office at 40th Wall Street, Suite #2725, New York, New York 10005, United States of America.
This website is operated by MergersUS Inc a US Corporation with registered office at